Government watchdog recommends tweaks to FDA accelerated approval program
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening conditions for which there is no alternative treatment. The approval then is contingent upon a confirmatory trial. But the FDA has had difficulty enforcing its post-marketing requirements.
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate (HPC; Makena), which was approved in 2011 to reduce the risk of recurrent preterm birth; and the Duchenne muscular dystrophy treatment eteplirsen (Exondys 51).
Federal watchdog cites concerns with FDA’s accelerated approval process
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency procedures.
Federal watchdog raises some concerns about the FDA’s accelerated approval program
The Office of Inspector General reviewed the FDA’s use of accelerated approval for 24 drugs, ultimately finding issues with the process for three of them.
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
Watchdog flags flaws in FDA's fast-track drug approvals
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional investigations revealed at least 40. Some meeting summaries were also found to be incomplete, according to Bloomberg .
Hosted on MSN11mon
Biogen ditches Aduhelm, an Alzheimer's drug that was approved amid controversy
Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...
STAT3d
Pharmalittle: We’re reading about FTC criticizing PBMs, an NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
BuzzFeed on MSN16d
This Is The Biggest Early Warning Sign Of Dementia That Most People Completely Miss
When we think about dementia, we often think of a person experiencing memory loss and confusion. While it’s true that these ...
Inhaling this gas could help treat Alzheimer's disease, study suggests
Scientists have discovered that inhaling xenon gas can activate brain immune cells to break down Alzheimer's-related plaques ...
BioSpace3d
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
Forbes8mon
Medicare Says It Expects To Spend $3.5 Billion In 2025 On Alzheimer’s Drug Leqembi, But This Is Unlikely
It’s worth revisiting what CMS and others, including KFF, appeared to believe would happen when the first beta amyloid-directed monoclonal antibody indicated for Alzheimer’s disease ...